Taeyeon Jeon, CEO of Alteogen, Interview ②


"Halozyme's Claims Violate Fundamental Principles of Patent Law"

"Even in the Worst Case, We Can Fight Again"

Taeyeon Jeon, CEO of Alteogen, stated during an interview with The Asia Business Daily at the company's headquarters in Yuseong-gu, Daejeon on April 23 that, regarding the ongoing patent dispute initiated by Halozyme in the United States against Alteogen, "So far, it is proceeding very favorably." Alteogen supplies its core enzyme, ALT-B4, which converts intravenous (IV) drugs into subcutaneous (SC) injections, to global pharmaceutical giants such as Merck (MSD). Halozyme, the leading company in this same market, has taken action by claiming that Alteogen has infringed on its patent. Out of several ongoing disputes, the first decision is set to be delivered in early June.


The disputes surrounding Alteogen are divided into three branches: a patent invalidation trial filed by Merck against Halozyme; another patent invalidation trial filed by Halozyme against Alteogen; and a patent infringement lawsuit filed by Halozyme against Merck at the U.S. District Court in New Jersey.

[Bio Story] First Decision in Alteogen-Halozyme Dispute Set for Early Next Month View original image

The first result to be announced will be the invalidation trial (PGR) that Merck filed with the U.S. Patent Trial and Appeal Board (PTAB). Merck is seeking to invalidate a patent on a modified hyaluronidase enzyme (MDASE) held by Halozyme. Hyaluronidase is an enzyme that helps drugs spread more easily under the skin when converting from IV to SC injection. Both Alteogen's ALT-B4 and Halozyme's proprietary enzyme belong to this class. If Halozyme is granted broad rights under this patent, it could restrict the development of follow-up products, including Keytruda SC, which Merck has launched in partnership with Alteogen. This is the reason Merck has directly initiated the invalidation proceedings.


Merck put forth two main arguments for invalidation. First, Halozyme is claiming rights not only over substances it has actually created and verified, but also over a vast number of theoretically possible modified enzymes. CEO Jeon described it as "the number of variants Halozyme claims is greater than all the grains of sand on Earth."


He also argued that such broad claims are inconsistent with the fundamental principles of patent law. To be granted a patent, the invention must be reproducible by other researchers based solely on the patent documents. Claiming exclusive rights to areas that have never actually been made or tested violates this principle.


Previously, Halozyme made two attempts to block this trial from proceeding. One was to petition the Director of the U.S. Patent and Trademark Office to dismiss the case at their discretion. The other was to challenge the eligibility of Merck's representatives by alleging improper involvement in the process. Both were rejected. The U.S. Patent Trial and Appeal Board's final decision on the validity of Halozyme's MDASE patent is scheduled for early June.

Taeyeon Jeon, CEO of Alteogen, held an interview with The Asia Business Daily at the company's headquarters in Yuseong-gu, Daejeon on the 23rd of last month. Regarding the patent dispute initiated by Halozyme in the United States against the company, he stated, "So far, it is proceeding very favorably." Photo by Donghun Jung

Taeyeon Jeon, CEO of Alteogen, held an interview with The Asia Business Daily at the company's headquarters in Yuseong-gu, Daejeon on the 23rd of last month. Regarding the patent dispute initiated by Halozyme in the United States against the company, he stated, "So far, it is proceeding very favorably." Photo by Donghun Jung

View original image

CEO Jeon cautioned against interpreting the outcome of this trial as being directly linked to Alteogen's business trajectory. Merck's PGR is a procedure solely to determine the validity of Halozyme's patent itself; it does not address whether Alteogen's ALT-B4 infringes upon that patent. Even if Halozyme prevails in the PGR and the patent survives, it does not automatically mean that ALT-B4 is infringing upon it.


Furthermore, Alteogen maintains that ALT-B4 itself lies outside the scope of Halozyme's patent rights. ALT-B4 is a unique variant with a structure different from the natural enzyme, and according to CEO Jeon, it operates via a mechanism different from what Halozyme's patent claims. In other words, ALT-B4 is a unique variant with a structure different from the natural enzyme and operates via a mechanism distinct from what is claimed by the Halozyme patent.


CEO Jeon said, "We have already obtained freedom-to-operate (FTO) opinions from top intellectual property law firms in the United States, stating that ALT-B4 does not infringe on Halozyme's patent. In addition, all eight global partner companies, including Merck, conducted their own patent due diligence prior to signing contracts, and all passed. The fact that these major pharmaceutical companies have directly verified and contracted with us is the strongest evidence."



Alteogen is also responding through local U.S. law firms to another invalidation trial (IPR) separately initiated by Halozyme targeting its manufacturing process patents. The contract with Merck clearly stipulates that, regardless of the outcome of any dispute, the royalties to be received by Alteogen will remain unchanged. CEO Jeon added, "Recently, even among our potential global partners in negotiations, there is a growing consensus that Halozyme's patent will likely be invalidated. In fact, the number of patent-related questions in new contract negotiations has noticeably decreased."

[Bio Story] First Decision in Alteogen-Halozyme Dispute Set for Early Next Month View original image


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing